NewAmsterdam Pharma

• Founded

  1 Jan 2019

Sources: ror.org

• NCT07794670

  Phase 2, Recruiting, 400 people, 31 Aug 2026

• NCT07219602

  Phase 3, Active, not recruiting, 300 people, 22 Oct 2025

• NCT06982508

  Phase 2, Recruiting, 100 people, 21 May 2025

• NCT06547359

  Phase 1, Completed, 94 people, 9 Aug 2024

• NCT06496243

  Phase 2, Recruiting, 69 people, 11 Jul 2024

• NCT06305559

  Phase 3, Active, not recruiting, 300 people, 12 Mar 2024

• NCT06250205

  Phase 1, Completed, 30 people, 8 Feb 2024

• NCT06081166

  Phase 1, Completed, 74 people, 13 Oct 2023

• NCT06048302

  Phase 1, Completed, 18 people, 21 Sept 2023

• NCT06005597

  Phase 3, Completed, 407 people, 22 Aug 2023

• NCT05972278

  Phase 1, Status unknown, 22 people, 2 Aug 2023

• NCT05425745

  Phase 3, Completed, 354 people, 21 Jun 2022

• NCT05421078

  Phase 2, Completed, 102 people, 16 Jun 2022

• NCT05266586

  Phase 2, Completed, 119 people, 4 Mar 2022

• NCT05202509

  Phase 3, Active, not recruiting, 9,541 people, 21 Jan 2022

• NCT05161715

  Phase 2, Completed, 13 people, 17 Dec 2021

• NCT05142722

  Phase 3, Completed, 2,530 people, 3 Dec 2021

• NCT04770389

  Phase 2, Completed, 112 people, 25 Feb 2021

• NCT04753606

  Phase 2, Completed, 120 people, 15 Feb 2021

• Lipoprotein (a) variability in high cardiovascular risk individuals with hypertriglyceridemia and controlled LDL-C on statin therapy in REDUCE-IT

  Consulting or advice, Grants or research support, 2 Sept 2026

• Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a)

  Grants or research support, 31 Aug 2026

• Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study

  Grants or research support, 28 Aug 2026

• Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial

  Grants or research support, 18 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov